CARGO Therapeutics, Inc. Common Stock (CRGX)
Automate Your Wheel Strategy on CRGX
With Tiblio's Option Bot, you can configure your own wheel strategy including CRGX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CRGX
- Rev/Share 0.0
- Book/Share 5.9027
- PB 0.781
- Debt/Equity 0.1078
- CurrentRatio 6.3006
- ROIC -0.751
- MktCap 212582562.0
- FreeCF/Share -3.1489
- PFCF -1.4108
- PE -1.0204
- Debt/Assets 0.0841
- DivYield 0
- ROE -0.5844
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 4
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | CRGX | Chardan Capital Markets | Buy | Neutral | -- | -- | Jan. 30, 2025 |
| Downgrade | CRGX | H.C. Wainwright | Buy | Neutral | -- | -- | Jan. 30, 2025 |
| Downgrade | CRGX | Jefferies | Buy | Hold | $32 | $3 | Jan. 30, 2025 |
| Downgrade | CRGX | JP Morgan | Overweight | Underweight | -- | -- | Jan. 30, 2025 |
| Downgrade | CRGX | Piper Sandler | Overweight | Neutral | $34 | $4 | Jan. 30, 2025 |
| Downgrade | CRGX | Truist | Buy | Hold | $32 | $7 | Jan. 30, 2025 |
| Downgrade | CRGX | William Blair | Outperform | Market Perform | -- | -- | Jan. 30, 2025 |
News
Levi & Korsinsky Investigates Possible Securities Fraud Violations by CARGO Therapeutics, Inc. (CRGX)
Published: February 10, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 10, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of CARGO Therapeutics, Inc. ("CARGO Therapeutics, Inc.") (NASDAQ:CRGX) concerning possible violations of federal securities laws. On January 29, 2025, CARGO announced in a press release that it "has elected to discontinue FIRCE-1, a Phase 2 clinical study of firi-cel for patients with large B-cell lymphoma (LBCL) whose disease relapsed or was refractory (R/R) to CD19 CAR T-cell therapy.
Read More
CARGO Therapeutics, Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
Published: February 10, 2025 by: Accesswire
Sentiment: Neutral
LOS ANGELES, CA / ACCESS Newswire / February 10, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CARGO Therapeutics, Inc. ("CARGO" or "the Company") (NASDAQ:CRGX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Read More
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against CARGO Therapeutics, Inc. (CRGX) And Encourages Shareholders to Reach Out
Published: February 10, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CARGO Therapeutics, Inc. ("CARGO" or "the Company") (NASDAQ:CRGX). Investors who purchased CARGO securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CRGX.
Read More
About CARGO Therapeutics, Inc. Common Stock (CRGX)
- IPO Date 2023-11-13
- Website https://cargo-tx.com
- Industry Biotechnology
- CEO Anup Radhakrishnan
- Employees 167